Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 838 results for score

  1. Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)

    NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .

  2. Lumbar infusion test for the investigation of normal pressure hydrocephalus (IPG263)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

  3. Percutaneous laser coronary angioplasty (IPG378)

    Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.

  4. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

  5. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.

  6. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    primary outcome should be global improvement in IBS symptoms, with symptom scores recorded using a validated scale. Health-related...

  7. Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)

    NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms

  8. Cardiovascular disease prevention: primary prevention with lipid lowering therapies (IND229)

    This indicator covers the percentage of patients with a cardiovascular disease risk assessment score of 10% or more who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM211

  9. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  10. Tonsillectomy using ultrasonic scalpel (IPG178)

    Evidence-based recommendations on tonsillectomy using ultrasonic scalpel. This involves using high-energy waves to cut the tonsils out and stop the bleeding at the same time.

  11. Phrenic nerve transfer in brachial plexus injury (IPG468)

    Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.

  12. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (IPG347)

    Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.

  13. Predictors of acute physical risk:- What clinical and biochemical markers are the best predictors of acute physical risk for people with eating disorders?

    Validated tools (such as Acute Physiology and Chronic Health Evaluation [APACHE] scores) are central to risk prediction in other areas...

  14. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  15. Balloon kyphoplasty for vertebral compression fractures (IPG166)

    Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.